A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes

Exclusion Criteria

• •1. Poor blood pressure control at screening.
• •2. Known or suspected allergy to investigational drug products or related products; or a history of multiple and/or severe allergies to drugs or foods.
• •3. Serious cardiovascular and cerebrovascular diseases within 6 months prior to screening.
• •4. Positive test for hepatitis B surface antigen (HBsAg), HIV antibody, treponema pallidum specific antibody, or hepatitis C virus antibody; or the investigator judges that the subject is in the incubation or active phase of the above infection.
• •5. Malignancy or history of malignancy within 5 years prior to screening.
• •6. Participation in any clinical trial of an approved or unapproved investigational drug/medical device within 90 days prior to screening.
• •7. Any other condition judged by the investigator to be likely to affect the subject's safety or interfere with the evaluation of trial results.